Literature DB >> 6305984

Double strand DNA cleavage by type II DNA topoisomerase from Drosophila melanogaster.

M Sander, T Hsieh.   

Abstract

The purified type II DNA topoisomerase from the embryos of Drosophila melanogaster exists in its native form as a dimer of 170,000-dalton polypeptides. In addition to the 170,000-dalton polypeptides, 3 polypeptides with molecular weights of 151,000, 141,000, and 132,000 were resolved when the enzyme was analyzed by electrophoresis under denaturing conditions. All four polypeptides can participate in the topoisomerase cleavage reaction and form covalent complexes with the cleaved DNA. Furthermore, immunochemical and biochemical data showed that they are structurally related and, therefore, the smaller polypeptides are likely generated from the 170,000-dalton polypeptide by proteolysis. The double strand DNA cleavage reaction of Drosophila topoisomerase has different site specificity from the Escherichia coli DNA gyrase-effected reaction. However, they result in an identical DNA structure at the cleavage site, which is a staggered double strand break with 4-nucleotide long 5'-protruding ends. The 3'-ends at the site of cleavage by Drosophila topoisomerase II have free hydroxyl groups and can be extended by exactly 4 nucleotides with T4 DNA polymerase, while the 5'-ends are covalently linked to the topoisomerase molecules. This similarity in cleavage site structure for Drosophila topoisomerase II and E. coli DNA gyrase suggests that they share some fundamental features in their mechanism of action.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6305984

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  95 in total

1.  Position-specific effect of ribonucleotides on the cleavage activity of human topoisomerase II.

Authors:  Y Wang; A Thyssen; O Westergaard; A H Andersen
Journal:  Nucleic Acids Res       Date:  2000-12-15       Impact factor: 16.971

2.  An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo.

Authors:  G Hong; K N Kreuzer
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

3.  Hydropathic analysis of the free energy differences in anthracycline antibiotic binding to DNA.

Authors:  Derek J Cashman; J Neel Scarsdale; Glen E Kellogg
Journal:  Nucleic Acids Res       Date:  2003-08-01       Impact factor: 16.971

4.  Incomplete reversion of double stranded DNA cleavage mediated by Drosophila topoisomerase II: formation of single stranded DNA cleavage complex in the presence of an anti-tumor drug VM26.

Authors:  M P Lee; T Hsieh
Journal:  Nucleic Acids Res       Date:  1992-10-11       Impact factor: 16.971

5.  Evaluation of sequence motifs found in scaffold/matrix-attached regions (S/MARs).

Authors:  I Liebich; J Bode; I Reuter; E Wingender
Journal:  Nucleic Acids Res       Date:  2002-08-01       Impact factor: 16.971

6.  The recognition of DNA cleavage sites by porcine spleen topoisomerase II.

Authors:  H W Huang; J K Juang; H J Liu
Journal:  Nucleic Acids Res       Date:  1992-02-11       Impact factor: 16.971

7.  Probing conformational changes in human DNA topoisomerase IIα by pulsed alkylation mass spectrometry.

Authors:  Yu-Tsung Chen; Tammy R L Collins; Ziqiang Guan; Vincent B Chen; Tao-Shih Hsieh
Journal:  J Biol Chem       Date:  2012-06-07       Impact factor: 5.157

8.  A naturally chimeric type IIA topoisomerase in Aquifex aeolicus highlights an evolutionary path for the emergence of functional paralogs.

Authors:  Elsa M Tretter; Jeffrey C Lerman; James M Berger
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-12       Impact factor: 11.205

9.  Sequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivative.

Authors:  P Fossé; B René; M Le Bret; C Paoletti; J M Saucier
Journal:  Nucleic Acids Res       Date:  1991-06-11       Impact factor: 16.971

Review 10.  Molecular biology of therapy-related leukaemias.

Authors:  Melanie Joannides; David Grimwade
Journal:  Clin Transl Oncol       Date:  2010-01       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.